论文部分内容阅读
心房颤动是肥厚型心肌病最常见的心律失常,心房颤动的发作增加肥厚型心肌病心力衰竭症状及住院率,影响患者生活质量,增加缺血性卒中及心血管死亡风险。肥厚型心肌病合并心房颤动的抗凝治疗有助于改善预后,但抗凝治疗的启动时机仍有争议。近年来新型口服抗凝药(NOAC)已广泛用于心房颤动的抗凝治疗,但在肥厚型心肌病伴发心房颤动人群中的应用经验不多。
Atrial fibrillation is the most common arrhythmia of hypertrophic cardiomyopathy. The onset of atrial fibrillation increases the symptoms and hospitalization rates of heart failure and affects the quality of life of patients with hypertrophic cardiomyopathy and increases the risk of ischemic stroke and cardiovascular death. Anticoagulant therapy for hypertrophic cardiomyopathy with atrial fibrillation can improve outcomes, but the timing of initiation of anticoagulation remains controversial. In recent years, new oral anticoagulants (NOACs) have been widely used in the anticoagulant therapy of atrial fibrillation, but little is known about their application in patients with hypertrophic cardiomyopathy associated with atrial fibrillation.